MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by WELLS, J. N.
Right arrow Articles by HARDMAN, J. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by WELLS, J. N.
Right arrow Articles by HARDMAN, J. G.

Molecular Pharmacology, Vol 11, 775-783, Copyright © 1975 by the American Society for Pharmacology and Experimental Therapeutics

Phosphodiesterases from Porcine Coronary Arteries: Inhibition of Separated Forms by Xanthines, Papaverine, and Cyclic Nucleotides

J. N. WELLS 1, Y. J. WU 1, C. E. BAIRD 1, and J. G. HARDMAN 1

1 Department of Physiology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232

This study was conducted to evaluate the possibility of selective inhibition of either guanosine cyclic 3',5'-monophosphate or adenosine cyclic 3',5'-monophosphate phosphodiesterase activities of pig coronary arteries. Two peaks (I and II) of cyclic nucleotide phosphodiesterase activity and a heat-stable, nondialyzable activator of peak I can be resolved from the intima plus media layer of pig coronary arteries by DEAE-cellulose chromatography. Peak I catalyzes the hydrolysis of both cyclic GMP and cyclic AMP, but it has a much lower apparent Km (1-4 µM) for cyclic GMP than for cyclic AMP (40-100 µM). Peak II activity is relatively specific for cyclic AMP and exhibits apparent negative cooperative behavior. Papaverine, 1-methyl-3-isobutylxanthine (MIX), 3',5'-cyclic nucleotides, and some 3',5'-cyclic nucleotide derivatives inhibit these phosphodiesterases to different degrees. For example, papaverine is 3-4 times more potent as an inhibitor of peak II than of peak I while MIX is 5-6 times more potent as an inhibitor of peak I than of peak II activity. Theophylline shows little selectivity for either form. The degree of inhibition of peak I by each agent is virtually independent of the cyclic nucleotide used as substrate. Hydrolysis of cyclic AMP by peak I activity is decreased by cyclic GMP more effectively than cyclic GMP hydrolysis is decreased by cyclic AMP. Ki values for inhibition of peak I activity by cyclic GMP and cyclic AMP correspond to their respective apparent Km values. Cyclic GMP also inhibits the hydrolysis of cyclic AMP by peak II, and it is as effective as MIX in this regard. The effects of none of the above agents on peak I were altered by the presence or absence of heat-stable, nondialyzable activator. N2,2'-O-Dibutyryl cyclic GMP, 8-bromo cyclic GMP, and N6,2'-O-dibutyryl cyclic AMP are, in general, more potent than theophylline as inhibitors of both forms of phosphodiesterase. 8-Bromo cyclic GMP and dibutyryl cyclic GMP are about 10 times more potent as inhibitors of peak I activity with either substrate than of peak II activity, whereas dibutyryl cyclic AMP is about 10 times more potent as an inhibitor of peak II activity than of peak I activity. 8-Bromo cyclic GMP is 4-6 times more potent as an inhibitor of fully activated peak I with either substrate than of activator-deficient peak I activity, but effects of dibutyryl cyclic AMP or dibutyryl cyclic GMP are changed very little by the presence of the activator. These data suggest the possibility of selective pharmacological regulation of cyclic GMP or cyclic AMP levels through selective inhibition of coronary artery phosphodiesterase activities.

Note:
ACKNOWLEDGMENT We thank Miss Sherry Burnitt for her expert technical help.

Submitted on March 17, 1975




This article has been cited by other articles:


Home page
J. Neurosci.Home page
V. M. Sandler and J.-G. Barbara
Calcium-Induced Calcium Release Contributes to Action Potential-Evoked Calcium Transients in Hippocampal CA1 Pyramidal Neurons
J. Neurosci., June 1, 1999; 19(11): 4325 - 4336.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
F. Bilgen, M. F. Yapici, A. SerbetcioGlu, I. A. Tarhan, T. Coruh, and A. Ozler
Effect of Normothermic Papaverine to Relieve Intraoperative Spasm of the Internal Thoracic Artery
Ann. Thorac. Surg., September 1, 1996; 62(3): 769 - 771.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
H. Yu, S. J. Suchard, R. Nairn, and R. Jove
Dissociation of Mitogen-activated Protein Kinase Activation from the Oxidative Burst in Differentiated HL-60 Cells and Human Neutrophils
J. Biol. Chem., June 30, 1995; 270(26): 15719 - 15724.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
J Wu, P Dent, T Jelinek, A Wolfman, M. Weber, and T. Sturgill
Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3',5'-monophosphate
Science, November 12, 1993; 262(5136): 1065 - 1069.
[Abstract] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1975 by the American Society for Pharmacology and Experimental Therapeutics